The medical community is abuzz about Retatrutide 120 , a twin-action therapy showing impressive results in early trials . This groundbreaking compound, a glucagon-like peptide-1 receptor alongside a glucose-dependent insulinotropic compound, appears to effectively reduce body size and positively affect metabolic function . Clinicians are suggesting